Replies to post #245419 on Biotech Values

[vinmantoo]

ENTA, on the other hand, has a lot riding on clinical data yet to be reported. The other side of the coin is that, if ENTA’s COVID and RSV programs bear fruit, the upside is colossal.

I was hoping for some movement on the third HBV drug to combine with EDP-514 and a nuc but no clear guidance on a candidate has been forthcoming. I would love to have that as it would give ENTA three shots on goal.